CN120305258A - 小分子cd-47抑制剂与其它抗癌剂的组合 - Google Patents

小分子cd-47抑制剂与其它抗癌剂的组合 Download PDF

Info

Publication number
CN120305258A
CN120305258A CN202510514794.1A CN202510514794A CN120305258A CN 120305258 A CN120305258 A CN 120305258A CN 202510514794 A CN202510514794 A CN 202510514794A CN 120305258 A CN120305258 A CN 120305258A
Authority
CN
China
Prior art keywords
cancer
compound
combination
certain embodiments
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510514794.1A
Other languages
English (en)
Chinese (zh)
Inventor
穆拉利达拉·拉马钱德拉
波塔伊尔·戈文丹·奈尔·萨斯库马
G·C·达吉纳卡特
K·A·巴尔库德鲁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregini Oncology Co ltd
Original Assignee
Oregini Oncology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregini Oncology Co ltd filed Critical Oregini Oncology Co ltd
Publication of CN120305258A publication Critical patent/CN120305258A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202510514794.1A 2018-11-08 2019-11-08 小分子cd-47抑制剂与其它抗癌剂的组合 Pending CN120305258A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201841042108 2018-11-08
IN201841042108 2018-11-08
CN201980071532.5A CN112930181B (zh) 2018-11-08 2019-11-08 小分子cd-47抑制剂与其它抗癌剂的组合
PCT/IB2019/059602 WO2020095256A1 (en) 2018-11-08 2019-11-08 Combination of small molecule cd-47 inhibitors with other anti-cancer agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980071532.5A Division CN112930181B (zh) 2018-11-08 2019-11-08 小分子cd-47抑制剂与其它抗癌剂的组合

Publications (1)

Publication Number Publication Date
CN120305258A true CN120305258A (zh) 2025-07-15

Family

ID=69159806

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510514794.1A Pending CN120305258A (zh) 2018-11-08 2019-11-08 小分子cd-47抑制剂与其它抗癌剂的组合
CN201980071532.5A Active CN112930181B (zh) 2018-11-08 2019-11-08 小分子cd-47抑制剂与其它抗癌剂的组合

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980071532.5A Active CN112930181B (zh) 2018-11-08 2019-11-08 小分子cd-47抑制剂与其它抗癌剂的组合

Country Status (14)

Country Link
US (3) US11311517B2 (enExample)
EP (1) EP3876931A1 (enExample)
JP (2) JP7623279B2 (enExample)
KR (1) KR20210088584A (enExample)
CN (2) CN120305258A (enExample)
AU (1) AU2019375193A1 (enExample)
BR (1) BR112021008781A2 (enExample)
CA (1) CA3118843A1 (enExample)
EA (1) EA202190776A1 (enExample)
IL (1) IL282972B2 (enExample)
MX (2) MX2021005240A (enExample)
PH (1) PH12021550832A1 (enExample)
SG (1) SG11202104192TA (enExample)
WO (1) WO2020095256A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3087841A1 (en) * 2018-01-12 2019-07-18 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
JP2024508395A (ja) * 2021-02-10 2024-02-27 グレート ノベル セラピューティクス バイオテック アンド メディカルズ コーポレイション がんに対する免疫応答を刺激する又は免疫抑制を克服するための医薬組み合わせ及び方法
CN113018415B (zh) * 2021-03-17 2022-07-01 遵义医科大学 一种药物组合及其应用
CN113750215B (zh) * 2021-09-24 2023-06-23 暨南大学 用于治疗肿瘤的联合药物
AU2024363740A1 (en) 2023-10-19 2026-04-02 Aurigene Oncology Limited Pharmaceutically acceptable salt of a cd47-sirp alpha pathway inhibitor
WO2025229631A2 (en) * 2024-05-03 2025-11-06 Aurigene Oncology Limited A CD47-SIRPα BLOCKING AGENT FOR THE TREATMENT OF CANCER
WO2025229629A1 (en) 2024-05-03 2025-11-06 Aurigene Oncology Limited Combination therapy using a cd47-sirp-alpha blocking agent and azacitidine
CN118453879B (zh) * 2024-05-23 2025-10-03 大连医科大学附属第二医院 恩杂鲁胺与铜离子载体联合在制备前列腺癌治疗药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2104501B1 (en) * 2006-12-13 2014-03-12 Merck Sharp & Dohme Corp. Methods of cancer treatment with igf1r inhibitors
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
HUE038169T2 (hu) 2013-09-06 2018-09-28 Aurigene Discovery Tech Ltd 1,2,4-Oxadiazol származékok mint immunomodulátorok
BR112017019304A2 (pt) 2015-03-10 2018-05-08 Aurigene Discovery Technologies Limited compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
KR102894264B1 (ko) * 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
EP3283175B1 (en) 2015-04-14 2026-05-06 The Procter & Gamble Company Solid conditioning composition
CN104804093A (zh) 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
WO2017053423A1 (en) 2015-09-21 2017-03-30 Erasmus University Medical Center Anti-cd47 antibodies and methods of use
EP3454879B1 (en) 2016-05-10 2021-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) New compounds and pharmaceutical use thereof in the treatment of cancer
EP3243522A1 (en) 2016-05-10 2017-11-15 Université Pierre et Marie Curie (Paris 6) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
AU2017345500B2 (en) * 2016-10-20 2022-03-10 Aurigene Oncology Limited Dual inhibitors of vista and PD-1 pathways
CA3087841A1 (en) * 2018-01-12 2019-07-18 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
CN118236374A (zh) * 2018-03-14 2024-06-25 奥瑞基尼肿瘤有限公司 使用1,2,4-噁二唑化合物调节tigit和pd-1信号传导途径的方法

Also Published As

Publication number Publication date
US12268670B2 (en) 2025-04-08
PH12021550832A1 (en) 2021-10-04
MX2021005240A (es) 2021-06-18
CN112930181B (zh) 2025-05-13
SG11202104192TA (en) 2021-05-28
JP2022507025A (ja) 2022-01-18
IL282972B2 (en) 2025-06-01
CA3118843A1 (en) 2020-05-14
US11311517B2 (en) 2022-04-26
IL282972B1 (en) 2025-02-01
JP2025063207A (ja) 2025-04-15
MX2024006094A (es) 2024-05-30
EA202190776A1 (ru) 2021-09-20
US20200147054A1 (en) 2020-05-14
EP3876931A1 (en) 2021-09-15
AU2019375193A1 (en) 2021-05-13
CN112930181A (zh) 2021-06-08
US20220241248A1 (en) 2022-08-04
BR112021008781A2 (pt) 2021-08-03
US20250177358A1 (en) 2025-06-05
WO2020095256A1 (en) 2020-05-14
IL282972A (en) 2021-06-30
JP7623279B2 (ja) 2025-01-28
KR20210088584A (ko) 2021-07-14

Similar Documents

Publication Publication Date Title
CN112930181B (zh) 小分子cd-47抑制剂与其它抗癌剂的组合
JP7032583B2 (ja) アルギナーゼ活性を阻害する組成物及び方法
JP7438955B2 (ja) Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４－オキサジアゾール化合物
CA3085634C (en) A conjugate of a tubulysin analog with branched linkers
JP2021193100A (ja) 免疫調節剤としての１，２，４−オキサジアゾールおよびチアジアゾール化合物
KR20190067235A (ko) Vista 및 pd-1 경로의 이중 억제제
US20230404986A1 (en) Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor
KR20170125931A (ko) 면역조절제로서의 3-치환된 1,3,4-옥사다이아졸 및 티아다이아졸 화합물
TW201420117A (zh) 抗體－藥物複合體
KR20180059544A (ko) 글루타미나제 억제제와 면역-종양학적 약제에 의한 병용 요법
WO2018047143A1 (en) Vista signaling pathway inhibitory compounds useful as immunomodulators
JP7417804B2 (ja) １，２，４－オキサジアゾール化合物を用いてｔｉｇｉｔおよびｐｄ－１のシグナル伝達経路をモジュレートする方法
EA045738B1 (ru) Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами
EA044002B1 (ru) 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47
EA049945B1 (ru) 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination